Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor

被引：20
|
作者：
Imaeda, Yasuhiro [1 ]
Tokuhara, Hidekazu [1 ]
Fukase, Yoshiyuki [1 ]
Kanagawa, Ray [1 ]
Kajimoto, Yumiko [1 ]
Kusumoto, Keiji [1 ]
Kondo, Mitsuyo [1 ]
Snell, Gyorgy [2 ]
Behnke, Craig A. [2 ,3 ]
Kuroita, Takanobu [1 ]
机构：
[1] Takeda Pharmaceut Co Ltd, Pharmaceut Res Div, 26-1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 2518555, Japan
[2] Takeda Calif Inc, 10410 Sci Ctr Dr, San Diego, CA 92121 USA
[3] Sapphire Energy Inc, 9363 Towne Ctr Dr, San Diego, CA 92121 USA
来源：
ACS MEDICINAL CHEMISTRY LETTERS | 2016年 / 7卷 / 10期
基金：
美国国家卫生研究院;
关键词：
Renin inhibitor; TAK-272; benzimidazole; hypertension; SBDD; dTg rat; HYPERTENSION; PIPERIDINES; EFFICIENCY; ALISKIREN; DESIGN; SYSTEM;
D O I：
10.1021/acsmedchemlett.6b00251
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The aspartic proteinase renin is an attractive target for the treatment of hypertension and cardiovascular/renal disease such as chronic kidney disease and heart failure. We introduced an S1' site binder into the lead compound 1 guided by structure-based drug design (SBDD), and further optimization of physicochemical properties led to the discovery of benzimidazole derivative 10 (1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-yl)carbonylpiperidin-3-yl]-1H-benzimidazole-2-carboxamide hydrochloride, TAK-272) as a highly potent and orally active renin inhibitor. Compound 10 demonstrated good oral bioavailability (BA) and long-lasting efficacy in rats. Compound 10 is currently in clinical trials.
引用
收藏
页码：933 / 938
页数：6
相关论文
共 50 条
  • [41] HEMODYNAMIC MECHANISM OF ACTION OF A NOVEL, NONPEPTIDIC, AND ORALLY ACTIVE RENIN INHIBITOR IN ANESTHETIZED DOGS
    CALZADILLA, SV
    WESSALE, JL
    KLEINERT, HD
    KOVAR, PJ
    BOYD, SA
    BAKER, WR
    FASEB JOURNAL, 1992, 6 (04): : A1293 - A1293
  • [42] DESIGN AND SYNTHESIS OF NOVEL POTENT, NON-PEPTIDE AND ORALLY ACTIVE RENIN INHIBITORS.
    Grutter, M.
    Maibaum, J.
    Rasetti, V.
    Rueger, H.
    Goschke, R.
    Mah, R.
    Cohen, N. C.
    Rahuel, J.
    Cumin, F.
    Wood, J.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 1996, 52 : C583 - C583
  • [43] Discovery of PAT-1102, a Novel, Potent and Orally Active Histone Deacetylase Inhibitor with Antitumor Activity in Cancer Mouse Models
    Hiriyan, Jagadheshan
    Shivarudraiah, Prasad
    Gavara, Govindarajulu
    Annamalai, Pazhanimuthu
    Natesan, Selvakumar
    Sambasivam, Ganesh
    Sukumaran, Sunil K.
    ANTICANCER RESEARCH, 2015, 35 (01) : 229 - 237
  • [44] Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor
    Zhang, Hefeng
    Peng, Xia
    Dai, Yang
    Shao, Jingwei
    Ji, Yinchun
    Sun, Yiming
    Liu, Bo
    Cheng, Xu
    Ai, Jing
    Duan, Wenhu
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (07) : 3956 - 3975
  • [45] DESIGN AND SYNTHESIS OF AN ORALLY POTENT HUMAN RENIN INHIBITOR CONTAINING A NOVEL AMINO-ACID, CYCLOHEXYLNORSTATINE
    IIZUKA, K
    KAMIJO, T
    HARADA, H
    AKAHANE, K
    KUBOTA, T
    UMEYAMA, H
    KISO, Y
    JOURNAL OF THE CHEMICAL SOCIETY-CHEMICAL COMMUNICATIONS, 1989, (21) : 1678 - 1680
  • [46] A novel orally active inhibitor of HLE
    Varga, M
    Kapui, Z
    Bátori, S
    Nagy, LT
    Vasvári-Debreczy, L
    Mikus, E
    Urbán-Szabó, K
    Arányi, P
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2003, 38 (04) : 421 - 425
  • [47] Discovery of a potent, orally available tricyclic derivative as a novel BRD4 inhibitor for melanoma
    Horai, Yuhei
    Suda, Naoki
    Uchihashi, Shinsuke
    Katakuse, Mayako
    Shigeno, Tomomi
    Hirano, Takashige
    Takahara, Junichi
    Fujita, Tomoyuki
    Mukoyama, Yohei
    Haga, Yuji
    BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 93
  • [48] Discovery of WX486 as a novel, potent, selective, and orally bioavailable irreversible inhibitor of BTK
    Wu, Chengde
    Shen, Chunli
    Zhu, Yuchuan
    Hu, Guoping
    Lin, Jian
    Chen, Shuhui
    Xiao, Qiang
    Huang, Lu
    Chen, Hailiang
    Tu, Ronghua
    Xu, Yong
    Wang, Xuehai
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [49] HIGHLY POTENT, ORALLY ACTIVE DIESTER MACROCYCLIC HUMAN RENIN INHIBITORS
    WEBER, AE
    STEINER, MG
    KRIETER, PA
    COLLETTI, AE
    TATA, JR
    HALGREN, TA
    BALL, RG
    DOYLE, JJ
    SCHORN, TW
    STEARNS, RA
    MILLER, RR
    SIEGL, PKS
    GREENLEE, WJ
    PATCHETT, AA
    JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (21) : 3755 - 3773
  • [50] Sar in the alkoxy lactone series:: The discovery of DFP, a potent and orally active COX-2 inhibitor
    Leblanc, Y
    Roy, P
    Boyce, S
    Brideau, C
    Chan, CC
    Charleson, S
    Gordon, R
    Grimm, E
    Guay, J
    Léger, S
    Li, CS
    Riendeau, D
    Visco, D
    Wang, Z
    Webb, J
    Xu, LJ
    Prasit, P
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (15) : 2207 - 2212
12345